Evidence map›Paper›PMID 37619847›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2023

HER2-low expression in patients with advanced or metastatic solid tumors.

B Uzunparmak, C Haymaker, G Raso, S Masciari, L Wang, H Lin, A Gorur, B Kirby, A-M Cimo, A Kennon and 15 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. HER2-low and HER2-ultra-low salivary gland carcinomas: an exploratory study.Virchows Archiv : an international journal of pathology · 2026
    Article
  13. Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 1 institution in 1 country.

B UzunparmakDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
C HaymakerDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, USA.
G RasoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, USA.
S MasciariDepartment of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
L WangDepartment of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
H LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
A GorurDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
B KirbyDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
A-M CimoDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
A KennonDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
Q DingDepartment of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
G UrschelDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
Y YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
G FengDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
Y RizviDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
A HussainDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
C ZhuDepartment of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
P KimDepartment of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
G AbbadessaDepartment of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
V SubbiahDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
T A YapDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA.
J RodonDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
S A Piha-PaulDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
F Meric-BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
E E DumbravaDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: eeileana@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Convalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3M
NCATS NIH HHS UL1 TR003167NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundHuman epidermal growth factor receptor 2 (HER2)-low is a newly defined category with HER2 1+ or 2+ expression by immunohistochemistry (IHC) and lack of HER2 gene amplification measured by in situ hybridization (ISH). Much remains unknown about the HER2-low status across tumor types and changes in HER2 status between primary and metastatic samples. PATIENTS AND

methodsHER2 expression by IHC was evaluated in 4701 patients with solid tumors. We have evaluated the HER2 expression by IHC and amplification by ISH in paired breast and gastric/gastroesophageal (GEJ) primary and metastatic samples. HER2 expression was correlated with ERBB2 genomic alterations evaluated by next-generation sequencing (NGS) in non-breast, non-gastric/GEJ samples.

resultsHER2 expression (HER2 IHC 1-3+) was found in half (49.8%) of the cancers, with HER2-low (1 or 2+) found in many tumor types: 47.1% in breast, 34.6% in gastric/GEJ, 50.0% in salivary gland, 46.9% in lung, 46.5% in endometrial, 46% in urothelial, and 45.5% of gallbladder cancers. The concordance evaluation of HER2 expression between primary and metastatic breast cancer samples showed that HER2 3+ remained unchanged in 87.1% with a strong agreement between primary and metastatic samples, with a weighted kappa (Κ) of 0.85 (95% confidence interval 0.79-0.91). ERBB2 alterations were identified in 117 (7.5%) patients with non-breast, non-gastric/GEJ solid tumors who had NGS testing. Of 1436 patients without ERBB2 alterations, 512 (35.7%) showed any level HER2 expression by IHC.

conclusionOur results show that HER2-low expression is frequently found across tumor types. These findings suggest that many patients with HER2-low solid tumors might benefit from HER2-targeted therapies.

Indexed as

Breast NeoplasmsNeoplasms, Second PrimaryBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleGenomicsHumansImmunohistochemistryIn Situ HybridizationBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB2 amplificationHER2 amplificationHER2 expressionHER2-lowtargeted therapy

Identifiers

PMID37619847
PMCPMC11670753
OpenAlexW4386057282

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.